Tobert, Jonathan

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 2,479

Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

Armitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet

Lipoproteins and Cardiovascular HealthCancer, Lipids, and Metabolism

Cited by 801

HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment

HPS2-THRIVE Collaborative Group, Haynes, R., Jiang, L., Hopewell, J. C., Li, J., Chen, F., Parish, S., Landray, M. J., Collins, R., Armitage, J., et al. (2013) · European Heart Journal

Lipoproteins and Cardiovascular HealthBlood Pressure and Hypertension Studies

Cited by 676

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Smoking and adverse outcomes in patients with CKD: The Study of Heart and Renal Protection (SHARP)

Staplin, N., Haynes, R., Herrington, W. G., Reith, C., Cass, A., Fellström, B., Jiang, L., Kasiske, B. L., Krane, V., Levin, A., et al. (2016) · American Journal of Kidney Diseases

Smoking Behavior and CessationChronic Kidney Disease and Diabetes

Cited by 86

Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors

Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 75

Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol

Newman, C. B., & Tobert, J. A. (2023) · The Journal of Clinical Endocrinology & Metabolism

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 20